TN2015000277A1 - Bmp-6 antibodies - Google Patents

Bmp-6 antibodies

Info

Publication number: TN2015000277A1
Authority: TN; Tunisia
Prior art keywords: antibodies; bmp; antigen; binding fragments; anemia
Prior art date: 2012-12-17

Application number

TNP2015000277A

Other languages

English (en)

Inventor

Jeffrey Michael Witkin

Stephanie Marie Eaton Truhlar

Neungseon Seo

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-17

Filing date

2015-06-16

Publication date

2016-10-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49918813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2015000277(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-06-16 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2016-10-03 Publication of TN2015000277A1 publication Critical patent/TN2015000277A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TNP2015000277A 2012-12-17 2015-06-16 Bmp-6 antibodies TN2015000277A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261737859P	2012-12-17	2012-12-17
PCT/US2013/073239 WO2014099391A1 (fr)	2012-12-17	2013-12-05	Anticorps anti-bmp-6

Publications (1)

Publication Number	Publication Date
TN2015000277A1 true TN2015000277A1 (en)	2016-10-03

Family

ID=49918813

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2015000277A TN2015000277A1 (en)	2012-12-17	2015-06-16	Bmp-6 antibodies

Country Status (33)

Country	Link
US (2)	US8795665B2 (fr)
EP (1)	EP2931748B1 (fr)
JP (1)	JP6033459B2 (fr)
KR (1)	KR20150083918A (fr)
CN (1)	CN104870473B (fr)
AP (1)	AP2015008600A0 (fr)
AR (1)	AR093620A1 (fr)
AU (1)	AU2013363548A1 (fr)
BR (1)	BR112015012708A2 (fr)
CA (1)	CA2892911C (fr)
CL (1)	CL2015001639A1 (fr)
CY (1)	CY1118254T1 (fr)
DK (1)	DK2931748T3 (fr)
EA (1)	EA201590918A1 (fr)
ES (1)	ES2608381T3 (fr)
HR (1)	HRP20161587T1 (fr)
HU (1)	HUE032431T2 (fr)
IL (1)	IL239242A0 (fr)
LT (1)	LT2931748T (fr)
MA (1)	MA38161A1 (fr)
ME (1)	ME02515B (fr)
MX (1)	MX2015007831A (fr)
PE (1)	PE20151164A1 (fr)
PH (1)	PH12015501360A1 (fr)
PL (1)	PL2931748T3 (fr)
PT (1)	PT2931748T (fr)
RS (1)	RS55413B1 (fr)
SG (1)	SG11201504695QA (fr)
SI (1)	SI2931748T1 (fr)
TN (1)	TN2015000277A1 (fr)
TW (1)	TW201439118A (fr)
WO (1)	WO2014099391A1 (fr)
ZA (1)	ZA201504282B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR093620A1 (es)	2012-12-17	2015-06-10	Lilly Co Eli	Anticuerpos bmp-6
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
GB2550114A (en)	2016-05-03	2017-11-15	Kymab Ltd	Methods, regimens, combinations & antagonists
KR102492057B1 (ko) *	2016-06-15	2023-01-26	노파르티스 아게	골 형태형성 단백질 6(ｂｍｐ6)의 억제제를 사용한 질병의 치료 방법
GB201815629D0 (en)	2018-09-25	2018-11-07	Kymab Ltd	Antagonists
JP2022537142A (ja) *	2019-06-12	2022-08-24	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	骨形成タンパク質６に対するヒト抗体
AU2020356575A1 (en)	2019-09-27	2022-04-14	Disc Medicine, Inc.	Methods for treating myelofibrosis and related conditions
WO2021207072A1 (fr) *	2020-04-07	2021-10-14	Mabwell Therapeutics Inc.	Anticorps anti-tmprss6 et leurs utilisations
US20230174645A1 (en)	2020-05-13	2023-06-08	Disc Medicine, Inc.	Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN114075287B (zh) *	2020-08-18	2023-07-21	湖南远泰生物技术有限公司	人源化bcma抗体和bcma-car-t细胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002077006A1 (fr)	2001-03-23	2002-10-03	Human Genome Sciences, Inc.	Polynucleotides, polypeptides et anticorps de proteines de la morphogenese osseuse
CA2597925A1 (fr)	2005-02-16	2006-08-24	The General Hospital Corporation	Utilisation d'un produit d'hemojuvelin humain pour reguler le metabolisme dependant l'hepcidine
ES2766257T3 (es) *	2008-11-13	2020-06-12	Massachusetts Gen Hospital	Métodos y composiciones para regular la homeostasis del hierro mediante la modulación de bmp-6
US20110070242A1 (en) *	2009-09-01	2011-03-24	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods for Diagnosing and Treating Iron Dysregulation
AR093620A1 (es) *	2012-12-17	2015-06-10	Lilly Co Eli	Anticuerpos bmp-6

2013
- 2013-11-27 AR ARP130104361A patent/AR093620A1/es unknown
- 2013-12-02 TW TW102144085A patent/TW201439118A/zh unknown
- 2013-12-05 ES ES13818045.0T patent/ES2608381T3/es active Active
- 2013-12-05 JP JP2015547414A patent/JP6033459B2/ja not_active Expired - Fee Related
- 2013-12-05 CN CN201380066174.1A patent/CN104870473B/zh not_active Expired - Fee Related
- 2013-12-05 BR BR112015012708A patent/BR112015012708A2/pt not_active IP Right Cessation
- 2013-12-05 HU HUE13818045A patent/HUE032431T2/en unknown
- 2013-12-05 KR KR1020157015613A patent/KR20150083918A/ko not_active Abandoned
- 2013-12-05 HR HRP20161587TT patent/HRP20161587T1/hr unknown
- 2013-12-05 LT LTEP13818045.0T patent/LT2931748T/lt unknown
- 2013-12-05 SG SG11201504695QA patent/SG11201504695QA/en unknown
- 2013-12-05 MA MA38161A patent/MA38161A1/fr unknown
- 2013-12-05 PT PT138180450T patent/PT2931748T/pt unknown
- 2013-12-05 EP EP13818045.0A patent/EP2931748B1/fr active Active
- 2013-12-05 EA EA201590918A patent/EA201590918A1/ru unknown
- 2013-12-05 ME MEP-2016-233A patent/ME02515B/fr unknown
- 2013-12-05 PL PL13818045T patent/PL2931748T3/pl unknown
- 2013-12-05 AP AP2015008600A patent/AP2015008600A0/xx unknown
- 2013-12-05 CA CA2892911A patent/CA2892911C/fr not_active Expired - Fee Related
- 2013-12-05 RS RS20160958A patent/RS55413B1/sr unknown
- 2013-12-05 US US14/097,335 patent/US8795665B2/en not_active Expired - Fee Related
- 2013-12-05 MX MX2015007831A patent/MX2015007831A/es unknown
- 2013-12-05 DK DK13818045.0T patent/DK2931748T3/da active
- 2013-12-05 WO PCT/US2013/073239 patent/WO2014099391A1/fr not_active Ceased
- 2013-12-05 SI SI201330363A patent/SI2931748T1/sl unknown
- 2013-12-05 PE PE2015001017A patent/PE20151164A1/es not_active Application Discontinuation
- 2013-12-05 AU AU2013363548A patent/AU2013363548A1/en not_active Abandoned
2014
- 2014-06-26 US US14/316,137 patent/US8980582B2/en not_active Expired - Fee Related
2015
- 2015-06-04 IL IL239242A patent/IL239242A0/en unknown
- 2015-06-12 ZA ZA2015/04282A patent/ZA201504282B/en unknown
- 2015-06-12 CL CL2015001639A patent/CL2015001639A1/es unknown
- 2015-06-16 TN TNP2015000277A patent/TN2015000277A1/fr unknown
- 2015-06-16 PH PH12015501360A patent/PH12015501360A1/en unknown
2016
- 2016-11-24 CY CY20161101225T patent/CY1118254T1/el unknown

Also Published As

Publication number	Publication date
EP2931748A1 (fr)	2015-10-21
JP6033459B2 (ja)	2016-11-30
CA2892911C (fr)	2017-02-28
CN104870473A (zh)	2015-08-26
BR112015012708A2 (pt)	2017-09-12
PL2931748T3 (pl)	2017-05-31
MA38161A1 (fr)	2017-12-29
JP2016501273A (ja)	2016-01-18
KR20150083918A (ko)	2015-07-20
WO2014099391A1 (fr)	2014-06-26
MX2015007831A (es)	2015-08-20
CA2892911A1 (fr)	2014-06-26
ME02515B (fr)	2017-02-20
PH12015501360A1 (en)	2015-09-02
SG11201504695QA (en)	2015-07-30
AP2015008600A0 (en)	2015-07-31
AU2013363548A1 (en)	2015-05-28
PE20151164A1 (es)	2015-08-19
LT2931748T (lt)	2017-01-10
HRP20161587T1 (hr)	2017-01-13
AR093620A1 (es)	2015-06-10
EP2931748B1 (fr)	2016-10-05
ZA201504282B (en)	2017-11-29
RS55413B1 (sr)	2017-04-28
PT2931748T (pt)	2016-11-02
CL2015001639A1 (es)	2015-10-02
SI2931748T1 (sl)	2017-01-31
DK2931748T3 (da)	2017-01-02
US20140170161A1 (en)	2014-06-19
US8795665B2 (en)	2014-08-05
IL239242A0 (en)	2015-07-30
TW201439118A (zh)	2014-10-16
HUE032431T2 (en)	2017-09-28
US20140309404A1 (en)	2014-10-16
CY1118254T1 (el)	2017-06-28
ES2608381T3 (es)	2017-04-10
CN104870473B (zh)	2018-05-29
US8980582B2 (en)	2015-03-17
EA201590918A1 (ru)	2015-10-30
HK1209763A1 (en)	2016-04-08

Publication	Publication Date	Title
PH12015501360A1 (en)	2015-09-02	Bmp-6 antibodies
EA201791485A1 (ru)	2018-02-28	Анти-cd47-антитела и их применения
PH12017500864A1 (en)	2017-12-11	Anti-notch1 antibodies
EA201791693A1 (ru)	2018-05-31	Гетеродимерные иммуноглобулины
MX2020004503A (es)	2020-08-13	Anticuerpos cd3 humanizados o quimericos.
JOP20160131B1 (ar)	2022-03-14	الأجسام المضادة للعامل xi وطرق الاستخدام
EA201401077A1 (ru)	2015-02-27	Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
IN2014KN00848A (fr)	2015-10-02
PH12014502406A1 (en)	2015-01-12	Anti-il-23p19 antibodies
EA201890305A1 (ru)	2018-07-31	Гуманизированные или химерные cd3-антитела
MX2015012122A (es)	2016-11-08	Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
PH12017501077A1 (en)	2017-11-06	Compositions and methods for antibodies targeting bmp6
PH12016501366A1 (en)	2016-08-15	Novel anti-baff antibodies
EA201490850A1 (ru)	2015-03-31	Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
MX2015017853A (es)	2016-05-10	Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso.
MX2015011518A (es)	2016-02-03	Agentes de enlace de met y usos de los mismos.
MX2014004074A (es)	2014-06-05	Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
PH12015502829A1 (en)	2016-03-21	Lectin-like oxidized ldl receptor1 antibodies and methods of use
MX2013001267A (es)	2013-04-10	ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
MX2019009498A (es)	2019-10-02	Anticuerpos mimeticos de fgf21 y usos de los mismos.
HK1196856A (en)	2014-12-24	C10rf32 antibodies, and uses thereof for treatment of cancer
TN2013000068A1 (en)	2014-06-25	Anti-vegfr-3 antibody compositions
NZ626296A (en)	2016-12-23	Compositions and methods for antibodies targeting factor p